文献速递乳腺癌

奥拉帕利片联合艾日布林治疗既往接受蒽环类和紫杉类治疗的日本晚期或转移性三阴性乳腺癌患者的I/II期试验

A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.
PubMed 文献 · Eur J Cancer · 2019-01-28

这项多中心I/II期试验在既往接受蒽环类和紫杉类治疗的日本晚期或转移性三阴性乳腺癌患者中评估奥拉帕利片联合艾日布林。I期确定II期推荐剂量为奥拉帕利300 mg每日两次联合艾日布林1.4 mg/m²。II期24例患者客观缓解率为29.2%(独立评审,90%CI 14.6-47.9),中位无进展生存期4.2个月,但≥III级中性粒细胞减少和白细胞减少发生率达83.3%,发热性中性粒细胞减少33.3%。

要点

  • II期推荐剂量为奥拉帕利300 mg每日两次联合艾日布林1.4 mg/m²(第1、8天)。
  • II期24例患者客观缓解率29.2%(独立评审,90%CI 14.6-47.9)。
  • ≥III级不良事件以中性粒细胞减少(83.3%)、白细胞减少(83.3%)和发热性中性粒细胞减少(33.3%)常见。

核心结论

  • 奥拉帕利联合艾日布林对晚期或转移性三阴性乳腺癌显示抗肿瘤活性,但存在发热性中性粒细胞减少时须谨慎。

研究设计与样本

  • 多中心I/II期试验,纳入日本晚期或转移性三阴性乳腺癌患者,既往接受蒽环类和紫杉类治疗。
  • I期剂量递增:奥拉帕利片口服每日两次,从1级25 mg每日两次至7级300 mg每日两次,联合艾日布林1.4 mg/m²于第1、8天给药。
  • II期采用II期推荐剂量评估独立评审的缓解率,计划样本量24例,阈值10%。

主要发现

  • I期24例中1例发生剂量限制性毒性,II期推荐剂量确定为奥拉帕利300 mg每日两次联合艾日布林1.4 mg/m²。
  • II期24例患者中位给药周期数为5.5(范围1-28)。
  • II期客观缓解率为29.2%(独立评审,N=7/24,90%CI 14.6-47.9)。
  • 中位无进展生存期4.2个月(95%CI 3.0-7.4),中位总生存期14.5个月(95%CI 4.8-22.0)。
  • ≥III级不良事件包括中性粒细胞减少(83.3%)、白细胞减少(83.3%)、贫血(41.7%)、发热性中性粒细胞减少(33.3%)和血栓形成(8.3%)。

关键数值与推荐

  • I期生殖系BRCA1/2突变状态:I期3例、II期2例观察到突变。
  • 奥拉帕利Cmax和AUC随剂量增加呈剂量依赖性升高,艾日布林与奥拉帕利的药代动力学参数互不影响。

临床怎么用

  • 作者认为奥拉帕利联合艾日布林对晚期或转移性三阴性乳腺癌显示抗肿瘤活性,但存在发热性中性粒细胞减少时须谨慎。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We conducted a multicenter phase I/II trial of olaparib plus eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer (TNBC) to determine the recommended phase II dose (RP2D) (phase I) and to examine the efficacy and safety (phase II) (UMIN00009498) of the combined therapy. PATIENTS AND METHODS: In phase I, olaparib tablet was orally administered twice daily from level 1:25 mg BID to level 7:300 mg BID, with 1.4 mg/m2 of eribulin on days 1 and 8. In phase II, patients were treated with RP2D to assess the response rate (independent review). The planned sample size was 24 with a threshold of 10%. RESULTS: One of the 24 patients enrolled in phase I experienced dose-limiting toxicity. The RP2D was established as 300 mg twice daily for olaparib and 1.4 mg/m2 for eribulin. Among the 24 patients in phase II, the median number of administered courses was 5.5 (range: 1-28). Grade ≥III adverse events included neutropenia (83.3%), leucopenia (83.3%), anaemia (41.7%), febrile neutropenia (33.3%) and thrombosis (8.3%). The response rate was 29.2% (independent; N = 7/24; 90% confidence interval [CI]; 14.6-47.9). Median progression-free survival and overall survival were 4.2 (95% CI, 3.0-7.4) and 14.5 (95% CI, 4.8-22.0) months, respectively. Germline BRCA1/2 mutation status was observed in three patients in phase I and 2 patients in phase II, respectively. The Cmax and area under the curve for olaparib increased in a dose-dependent manner, and these parameters for eribulin and olaparib were not influenced by each other. CONCLUSIONS: Combination therapy of olaparib with eribulin shows antitumour activity against advanced or metastatic TNBC, but caution must be exercised in the presence of febrile neutropenia.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Yonemori K, Shimomura A, Yasojima H, et al. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. Eur J Cancer. 2019. PMID: 30703739. doi:10.1016/j.ejca.2018.11.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。